Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis E vaccine (recombinant)
- Development stage
- Unknown
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Yikening (also known as Hecolin) is a recombinant protein subunit vaccine developed by Xiamen Innovax Biotech for the prevention of hepatitis E virus (HEV) infection. It is the first HEV vaccine to be licensed globally, having received approval from the China Food and Drug Administration (CFDA) in 2011. The vaccine is composed of virus-like particles (VLPs) formed by the p239 protein, a truncated version of the HEV genotype 1 capsid protein expressed in *Escherichia coli*. Yikening is administered via intramuscular injection and is designed to induce high titers of neutralizing antibodies to protect against HEV infection. It is particularly recommended for high-risk populations, including travelers to endemic regions, women of childbearing age, and individuals with underlying chronic liver diseases. Ongoing clinical research continues to evaluate its safety and immunogenicity in specific patient populations, such as those with chronic hepatitis B-related cirrhosis.
- Brand names
- YikeningHecolin
- Other names
- HEV-239HEV239HEV 239Hepatitis E Vaccine (Recombinant, E. coli)
02
Targets
HEV ORF2 (Hepatitis E virus capsid protein)
Beyond the preview
Go deeper on hepatitis E vaccine (recombinant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis E vaccine (recombinant).